# What Is KLOW Peptide? A Plain-English Overview > What is KLOW peptide? A plain-English overview: KLOW is a four-peptide research blend — KPV, GHK-Cu, BPC-157, TB-500 — co-formulated at 80 mg. No blend trial. Component studies indexed here. Four distinct research peptides. One co-formulated vial. Every benefit claim is component-derived. No blend trial exists. ## In plain English KLOW peptide is four peptides sold together in one research vial, not one drug. The four are: KPV, a tiny anti-inflammatory protein fragment; GHK-Cu, a copper-carrying tripeptide that makes up most of the vial by weight and has decades of skin and tissue research behind it; BPC-157, a 15-amino-acid peptide studied mainly in rat tissue-repair and gut-healing models; and TB-500, a short peptide fragment associated with cell-migration and wound-closure studies in animals. None of the four is approved by the FDA for human use. The four-peptide combination has never been tested in any controlled study — meaning no experiment has ever compared KLOW-as-a-blend against taking just one ingredient, just two, or just a placebo. Everything claimed about the combination rests on the assumption that four complementary ingredients work better together than any one alone. That assumption may be reasonable, but it is not proven. This page is a plain-English introduction. What is KLOW peptide? That question answered in full, with citations, is below. ## What is KLOW peptide? — the four components KLOW is a co-formulation — a research abbreviation formed from the four constituent names. The canonical 80 mg vial breaks down as: - **GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex):** 50 mg, CAS 89030-95-5, MW 402.92 Da. The mass-dominant component at ~62.5% of the vial. A naturally occurring copper-chelated tripeptide first isolated from human plasma in 1973. Its endogenous plasma levels decline with age — from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4]. Research shows it stimulates collagen synthesis and modulates expression of approximately 31% of human protein-coding genes toward repair, antioxidant defense and DNA-fidelity programs [4][5]. - **BPC-157 (Body Protection Compound 157):** 10 mg, CAS 137525-51-0, MW 1419.53 Da. A synthetic 15-amino-acid peptide (sequence: GEPPPGKPADDAGLV) derived from a protein in human gastric juice. The most extensively studied arm in animal models: tendon healing [2], gut-ulcer protection [8], and a 2024 human pilot in interstitial cystitis (complete symptom resolution in 10/12, uncontrolled) [14]. A 2025 IV safety pilot in two adults found no adverse events at up to 20 mg IV [6]. - **TB-500 (Ac-LKKTETQ):** 10 mg, MW 889.02 Da. A synthetic N-acetylated heptapeptide corresponding to the actin-binding LKKTET motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). The important distinction: most efficacy data — including the foundational wound re-epithelialization result (+42% at day 4, +61% at day 7 vs saline) [1] — are for full-length Tbeta4, not the TB-500 fragment. The fragment shares the G-actin-sequestering motif; whether the broader activities transfer is not established [7]. - **KPV (Lys-Pro-Val):** 10 mg, CAS 67727-97-3, MW 342.44 Da. The C-terminal tripeptide (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Transported preferentially into inflamed gut epithelial cells via the PepT1 (SLC15A1) transporter (Km ~160 microM) [3]. Nanomolar KPV suppresses NF-kB nuclear import and reduces TNF-alpha, IL-6 and IL-1beta in cell culture; oral KPV reduced colitis severity in DSS and TNBS mouse models [3][9]. ## What is KLOW peptide used for — research context The research-use community positions KLOW primarily as a tissue-repair and anti-inflammatory stack. The logic: BPC-157 handles angiogenesis and gut-mucosal repair; TB-500/Tbeta4 drives cell migration and wound closure; GHK-Cu addresses matrix synthesis and collagen crosslinking; KPV specifically targets gut-mucosal NF-kB-driven inflammation. The gut-mucosa angle is the allocated research lens for this domain. The KPV arm has the most direct gut-mucosa evidence: PepT1-mediated uptake into intestinal epithelium is upregulated in inflamed tissue, and KPV has reduced colitis severity in controlled mouse models [3][9][10]. BPC-157 also has foundational cytoprotection and gut-healing data [8]. GHK-Cu operates more broadly across skin, matrix and gene expression. TB-500 targets wound closure and cell migration, with the Tbeta4 native-protein data as the reference point. KLOW is NOT a weight-loss or GLP-1 compound. None of its four components is an incretin, a glucagon-like peptide receptor agonist, or an established metabolic agent. This distinction matters: KLOW targets tissue repair and inflammation, not appetite regulation or glycemic control. See [KLOW research](/research) for the full mechanistic record. ## The honest gaps Three structural gaps define what is NOT known about KLOW peptide: 1. **No combination study.** The four-peptide blend has never been tested against monotherapy, any subset, or placebo. Every synergy argument is mechanistic extrapolation from single-component literature. 2. **Pharmacokinetic mismatch.** The two tripeptides (KPV, GHK-Cu) clear much faster than BPC-157, which itself has a very short half-life (under ~30 minutes in a formal rat PK study). The TB-500 fragment behaves differently from full-length Tbeta4. A single co-dissolved vial cannot hold all four at matched tissue exposures. 3. **Thin human data.** GHK-Cu's robust data are topical/cosmetic. BPC-157 has mainly rodent models plus a tiny 2025 IV safety pilot [6]. KPV human data are limited to delivery experiments and an IBD drug-program lineage. TB-500's best data are for the native 43-amino-acid protein. For the full safety picture and community-reported effects, see [KLOW effects](/effects). --- Four channels logged, four literatures cited — a research console that reads the component record and marks the blank rows honestly.